Alnylam Pharmaceuticals, Inc. (ALNY) belonging to the Healthcare sector has surged 0.78% and closed its last trading session at $113.8.
The company reported its EPS on 6/29/2017. Currently, the stock has a 1 Year Price Target of $109.47.
The consensus recommendation, according to Zacks Investment research, is 1.87. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 1.85 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2 and 2 respectively.
Alnylam Pharmaceuticals, Inc. on 6/29/2017 reported its EPS as $-1.21 with the analysts projecting the EPS of the stock as $-1.14. The company beat the analyst EPS Estimate with the difference of $-0.07. This shows a surprise factor of -0.061%.
Many analysts have provided their estimated foresights on Alnylam Pharmaceuticals, Inc. Earnings, with 16 analysts believing the company would generate an Average Estimate of $-1.27.
Whereas they predicted High and Low Earnings Estimate as $-0.78 and $-1.64 respectively. While in the same Quarter Previous year, the Actual EPS was $-1.21.
Analysts are also projecting an Average Revenue Estimate for Alnylam Pharmaceuticals, Inc. as $24700 in the Current Quarter. This estimate is provided by 16 analysts.
The High Revenue estimate is predicted as 64580, while the Low Revenue Estimate prediction stands at 15930. The company’s last year sales total was 13650.
For the Current Quarter, the growth estimate for Alnylam Pharmaceuticals, Inc. is -5%, while for the Next Quarter the stock growth estimate is -3%.
Insider Trades for Alnylam Pharmaceuticals, Inc. show that the latest trade was made on 12 Jun 2017 where Vaishnaw (Akshay K), the Officer completed a transaction type “Buy” in which 328 shares were traded at a price of $21.35.
Alnylam Pharmaceuticals, Inc. (ALNY) has the market capitalization of $10.36 Billion. The company rocked its 52-Week High of $118.4 and touched its 52-Week Low of $31.38.
The stock has Return on Assets (ROA) of -34.4 percent. Return on Equity (ROE) stands at -45.5% and Return on Investment (ROI) of -39.7 percent.
The stock is currently showing YTD performance of 203.95 Percent. The company has Beta Value of 2.99 and ATR value of 6.26. The Weekly and Monthly Volatility stands at 8.38% and 5.01%.